The effect of erythropoietin stimulation on bone marrow uptake of FDG has been well documented.
Similar metabolic activation of bone marrow with 18F-fluorocholine (FCH) has not been previously reported. FCH PET/CT was performed in a patient with biochemical recurrent prostate cancer who was receiving erythropoietin for hemochromatosis. Diffuse skeletal uptake of FCH was seen. 18F-Fluoride PET/CT performed the following day demonstrates multiple abnormal focal bone metastases. Generalized skeletal uptake of FCH results in poor contrast between the metastases compared to noninvolved bone. The metabolic activation of bone marrow by erythropoietin could result in false-negative FCH results for detecting bone metastases.
Written by:
Balogova S, Huchet V, Egrot C, Michaud L, Paycha F, Kerrou K, Montravers F, Cussenot O, Talbot JN. Are you the author?
Department of Nuclear Medicine, Hôpital Tenon AP-HP, Université Pierre et Marie Curie, Paris, France; Comenius University, Bratislava, Slovakia; and Department of Urology, Hôpital Tenon AP-HP, Université Pierre et Marie Curie, Paris, France.
Reference: Clin Nucl Med. 2013 Mar;38(3):200-2.
doi: 10.1097/RLU.0b013e31827a2294
PubMed Abstract
PMID: 23354033
UroToday.com Prostate Cancer Section
